Celltrion announces U.S. availability of Avtozma, tocilizumab biosimilar as a subcutaneous (SC) formulation

Celltrion Inc. announced that Avtozma (tocilizumab-anoh) subcutaneous (SC) formulation is now available to patients in the United States. With this launch, Celltrion’s Avtozma becomes one of the first tocilizumab biosimilars to have both an intravenous (IV) and a SC formulation approved by the FDA and available on the U.S. market.

“The introduction of AVTOZMA SC is a pivotal moment for Celltrion, underscoring our dedication to delivering effective, accessible and user-friendly therapies for patients with chronic inflammatory diseases,” said Thomas Nusbickel, Chief Commercial Officer of Celltrion USA. “By offering both IV and SC formulations, we aim to provide patients and healthcare professionals with greater flexibility in treatment decisions, while continuing to broaden our immunology portfolio with therapies that address diverse inflammatory pathways.”

The SC formulation of Avtozma  is indicated for the treatment of rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA). Avtozma  SC is available in a 162 mg/0.9 mL solution for injection in a single-dose prefilled syringe or a single-dose prefilled autoinjector, allowing patients the flexibility and convenience of administering their treatment at home.